Advertisement

Adrenal Glands pp 211-222 | Cite as

Neuroblastoma

  • Jed G. Nuchtern
  • Heidi V. Russell
  • Jason M. Shohet

Keywords

Clin Oncol Vasoactive Intestinal Peptide MYCN Amplification Neuroblastoma Tumor Autologous Stem Cell Rescue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bowman L, Grossmann M, Rill D, Brown M, et al. (1998) IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 92:1941–1949PubMedGoogle Scholar
  2. 2.
    Brodeur GM ( 2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3:203–216CrossRefPubMedGoogle Scholar
  3. 3.
    Brodeur GM, Maris JM (2002) Neuroblastoma. In: Pizzo PA, Poplack DG (eds) Principles and practice of pediatric oncology. Lippincott Williams & Wilkins, Philadelphia, p 895Google Scholar
  4. 4.
    Brodeur GM, Pritchard J, Berthold F, Carlsen NL, et al. (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466–1477PubMedGoogle Scholar
  5. 5.
    Brodeur GM, Nakagawara A, Yamashiro DJ, Ikegaki N, et al. (1997) Expression of TrkA, TrkB and TrkC in human neuroblastomas. J Neurooncol 31:49–55CrossRefPubMedGoogle Scholar
  6. 6.
    Cheung NK, Kushner BH, Cheung IY, Kramer K, et al. (1998) Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 16:3053–3060PubMedGoogle Scholar
  7. 7.
    Childs R, Chernoff A, Contentin N, Bahceci E, et al. (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750–758CrossRefPubMedGoogle Scholar
  8. 8.
    Coldman AJ, Fryer CJ, Elwood JM, Sonley MJ (1980) Neuroblastoma: influence of age at diagnosis, stage, tumor site, and sex on prognosis. Cancer 46:1896–1901PubMedGoogle Scholar
  9. 9.
    Cole MD, McMahon SB (1999) The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene 18:2916–2924CrossRefPubMedGoogle Scholar
  10. 10.
    D’Angio GJ, Evans AE, Koop CE (1971) Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1:1046–1049CrossRefPubMedGoogle Scholar
  11. 11.
    Davies RP, Slavotinek JP, Dorney SF (1990) VIP secreting tumours in infancy. A review of radiological appearances. Pediatr Radiol 20:504–508CrossRefPubMedGoogle Scholar
  12. 12.
    De Bernardi B, Pianca C, Pistamiglio P, Veneselli E, et al. (2001) Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases. J Clin Oncol 19:183–190PubMedGoogle Scholar
  13. 13.
    DuBois SG, Kalika Y, Lukens JN, Brodeur GM, et al. (1999) Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 21:181–189CrossRefPubMedGoogle Scholar
  14. 14.
    Eggert, A, Grotzer MA, Ikegaki N, Liu XG, et al. (2000) Expression of neurotrophin receptor TrkA inhibits angiogenesis in neuroblastoma. Med Pediatr Oncol 35:569–572CrossRefPubMedGoogle Scholar
  15. 15.
    Evans AE, Chatten J, D’Angio GJ, Gerson JM, et al. (1980) A review of 17 IV-S neuroblastoma patients at the Children’s Hospital of Philadelphia. Cancer 45:833–839PubMedGoogle Scholar
  16. 16.
    Evans AE, D’Angio GJ, Propert K, Anderson J, et al. (1987) Prognostic factor in neuroblastoma. Cancer 59:1853–1859PubMedGoogle Scholar
  17. 17.
    Funato M, Fujimura M, Shimada S, Takeuchi T,et al.(1982) Rapid changes of serum vasoactive intestinal peptide after removal of ganglioneuroblastoma with watery-diarrhea-hypokalemia-achlorhydria syndrome in a child. J Pediatr Gastroenterol Nutr 1:131–135PubMedGoogle Scholar
  18. 18.
    Garaventa A, De Bernardi B, Pianca C, Donfrancesco A, et al. (1993) Localized but unresectable neuroblastoma: treatment and outcome of 145 cases. Italian Cooperative Group for Neuroblastoma. J Clin Oncol 11:1770–9PubMedGoogle Scholar
  19. 19.
    Grupp SA, Stern JW, Bunin N, Nancarrow C, et al. (2000) Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol 18:2567–2575PubMedGoogle Scholar
  20. 20.
    Grupp SA, Bowman LC, von Allmen D, Guzikowski V,et al. (2002) Rapid sequence tandem transplant for advanced neuroblastoma: update and patterns of relapse. Adv Neuroblastoma Res 2002:120Google Scholar
  21. 21.
    Haase GM, O’Leary MC, Ramsay NK, Romansky SG (1991) Aggressive surgery combined with intensive chemotherapy improves survival in poor-risk neuroblastoma. J Pediatr Surg 26:1119–24CrossRefPubMedGoogle Scholar
  22. 22.
    Jereb B, Bretsky SS, Vogel R, Helson L (1984) Age and prognosis in neuroblastoma. Review of 112 patients younger than 2 years. Am J Pediatr Hematol Oncol 6: 233–243PubMedGoogle Scholar
  23. 23.
    Kaneko M, Iwakawa M, Ikebukuro K, Ohkawa H (1998) Complete resection is not required in patients with neuroblastoma under 1 year of age. J Pediatr Surg 33:1690–4CrossRefPubMedGoogle Scholar
  24. 24.
    Kaplan SJ, Holbrook CT, McDaniel HG, Buntain WL,et al. (1980) Vasoactive intestinal peptide secreting tumors of childhood. Am J Dis Child 134:21–24PubMedGoogle Scholar
  25. 25.
    Katzenstein HM, Bowman LC, Brodeur GM, Thorner PS, et al. (1998) Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy,and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience — a pediatric oncology group study. J Clin Oncol 16:2007–2017PubMedGoogle Scholar
  26. 26.
    Kiely EM (1993) Radical surgery for abdominal neuroblastoma. Semin Surg Oncol 9:489–92PubMedGoogle Scholar
  27. 27.
    Kletzel M, Katzenstein HM, Haut PR, Yu AL, et al. (2002) Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol 20:2284–2292CrossRefPubMedGoogle Scholar
  28. 28.
    Kushner BH, Gilbert F, Helson L (1986) Familial neuroblastoma. Case reports,literature review,and etiologic considerations. Cancer 57:1887–1893PubMedGoogle Scholar
  29. 29.
    Kushner BH, Cheung NK, LaQuaglia MP, Ambros PF, et al. (1996) Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol 14: 373–381PubMedGoogle Scholar
  30. 30.
    La Quaglia MP, Kushner BH, Heller G, Bonilla MA, et al. (1994) Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome. J Pediatr Surg 29:1162–6CrossRefPubMedGoogle Scholar
  31. 31.
    Look AT, Hayes FA, Shuster JJ, Douglass EC, et al. (1991) Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 9:581–591PubMedGoogle Scholar
  32. 32.
    Lovat PE, Ranalli M, Annichiarrico-Petruzzelli M, Bernassola F, et al. (2000) Effector mechanisms of fenretinideinduced apoptosis in neuroblastoma. Exp Cell Res 260: 50–60CrossRefPubMedGoogle Scholar
  33. 33.
    Lutz W, Schurmann J, Wenzel A, et al. (1996) Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 13:803–812PubMedGoogle Scholar
  34. 34.
    Maris JM, Weiss MJ, Guo C, Gerbing RB, et al. (2000) Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children’s Cancer Group study. J Clin Oncol 18:1888–1899PubMedGoogle Scholar
  35. 35.
    Maris JM, Weiss MJ, Mosse Y, Hii G, et al. (2002) Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12–13. Cancer Res 62:6651–6658PubMedGoogle Scholar
  36. 36.
    Matthay KK, Perez C, Seeger RC, Brodeur GM,et al.(1998) Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children’s Cancer Group study. J Clin Oncol 16:1256–1264PubMedGoogle Scholar
  37. 37.
    Matthay KK, Villablanca JG, Seeger RC, Stram DO, et al. (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 341:1165–1173CrossRefPubMedGoogle Scholar
  38. 38.
    Nitschke R, Smith EI, Shochat S, Altshuler G, et al. (1988) Localized neuroblastoma treated by surgery: a Pediatric Oncology Group Study. J Clin Oncol 6:1271–1279PubMedGoogle Scholar
  39. 39.
    Perel Y, Conway J, Kletzel M, Goldman J, et al. (1999) Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma. J Pediatr Hematol Oncol 21:13–18CrossRefPubMedGoogle Scholar
  40. 40.
    Pranzatelli MR (1992) The neurobiology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol 15: 186–228PubMedGoogle Scholar
  41. 41.
    Pranzatelli MR, Tate ED, Wheeler A, Bass N, et al. (2002) Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia. Pediatr Neurol 27:384–387CrossRefPubMedGoogle Scholar
  42. 42.
    Rees H, Markley MA, Kiely EM, Pierro A, Pritchard J (1998) Diarrhea after resection of advanced abdominal neuroblastoma: a common management problem. Surgery 123:568–72CrossRefPubMedGoogle Scholar
  43. 43.
    Rousseau RF, Haight AE, Hirschmann-Jax C, Yvon ES,et al. (2003) Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 101:1718–1726CrossRefPubMedGoogle Scholar
  44. 44.
    Rudnick E, Khakoo Y, Antunes NL, Seeger RC, et al. (2001) Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies — a report from the Children’s Cancer Group Study. Med Pediatr Oncol 36:612–622CrossRefPubMedGoogle Scholar
  45. 45.
    Schilling FH, Spix C, Berthold F, Erttmann R, et al. (2002) Neuroblastoma screening at one year of age. N Engl J Med 346:1047–1053CrossRefPubMedGoogle Scholar
  46. 46.
    Schwab M (1999) Oncogene amplification in solid tumors. Semin Cancer Biol 9:319–325CrossRefPubMedGoogle Scholar
  47. 47.
    Shamberger RC, Allarde-Segundo A, Kozakewich HP, Grier HE (1991) Surgical management of stage III and IV neuroblastoma: resection before or after chemotherapy? J Pediatr Surg 26:1113–8CrossRefPubMedGoogle Scholar
  48. 48.
    Shimada H (1992) Neuroblastoma. Pathology and biology. Acta Pathol Jpn 42:229–241Google Scholar
  49. 49.
    Shimada H, Chatten J, Newton WA Jr, Sachs N, et al. (1984) Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73:405–416PubMedGoogle Scholar
  50. 50.
    Shimada H, Ambros IM, Dehner LP, Hata J, et al. (1999) The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86:364–372CrossRefPubMedGoogle Scholar
  51. 51.
    Shimada H, Umehara S, Monobe Y, Hachitanda Y, et al. (2001) International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children’s Cancer Group. Cancer 92:2451–2461CrossRefPubMedGoogle Scholar
  52. 52.
    Shulkin BL, Shapiro B (1998) Current concepts on the diagnostic use of MIBG in children. J Nucl Med 39: 679–688PubMedGoogle Scholar
  53. 53.
    Strother D, Shuster JJ, McWilliams N, Nitschke R, et al. (1995) Results of pediatric oncology group protocol 8104 for infants with stages D and DS neuroblastoma. J Pediatr Hematol Oncol 17:254–259PubMedGoogle Scholar
  54. 54.
    Strother D, van Hoff J, Rao PV, Smith EI, et al. (1997) Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group. Eur J Cancer 33:2121–2125CrossRefPubMedGoogle Scholar
  55. 55.
    Tsuchida Y, Yokoyama J, Kaneko M, Uchino J, Iwafuchi M, Makino S, Matsuyama S, Takahashi H, Okabe I, Hashizume K, et al. (1992) Therapeutic significance of surgery in advanced neuroblastoma: a report from the study group of Japan. J Pediatr Surg 27:616–22CrossRefPubMedGoogle Scholar
  56. 56.
    van Noesel MM, Hahlen K, Hakvoort-Cammel FG, Egeler RM (1997) Neuroblastoma 4S: a heterogeneous disease with variable risk factors and treatment strategies. Cancer 80:834–843CrossRefPubMedGoogle Scholar
  57. 57.
    van Santen HM, de Kraker J, van Eck BL, de Vijlder JJ, et al. (2002) High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-metaiodobenzylguanidine treatment in children with neuroblastoma. Cancer 94:2081–2089CrossRefPubMedGoogle Scholar
  58. 58.
    von Schweinitz D, Hero B, Berthold F (2002) The impact of surgical radicality on outcome in childhood neuroblastoma. Eur J Pediatr Surg 12:402–9CrossRefPubMedGoogle Scholar
  59. 59.
    Westermann F, Schwab M (2002) Genetic parameters of neuroblastomas. Cancer Lett 184:127–47CrossRefPubMedGoogle Scholar
  60. 60.
    Woods WG, Gao RN, Shuster JJ, Robison LL, et al. (2002) Screening of infants and mortality due to neuroblastoma. N Engl J Med 346:1041–1046CrossRefPubMedGoogle Scholar
  61. 61.
    Yamamoto K, Ohta S, Ito E, Hayashi Y, et al. (2002) Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6months of age: cohort study in seven prefectures in Japan. J Clin Oncol 20:1209–1214CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Jed G. Nuchtern
  • Heidi V. Russell
  • Jason M. Shohet

There are no affiliations available

Personalised recommendations